definiens: shall mean the start of the Manufacturing of the first batch of CTM by [COMPANY] that issuitable for use in the FIH Study ) [ * * * ] ( ii ) Dosing of the first subject in the first FIH Study of such Candidate [ * * * ] ( iii ) [COMPANY] ’s selection of such Candidate for further Development in a Phase I Clinical Trial ( other than the FIHStudy ) or Phase II Clinical Trial including by selection as CAN based on [COMPANY] ’s CAN Selection Criteria [ * * * ] ( iv ) Dosing of the first subject in the first Phase I or Phase I / II Clinical Trial ( neither being the FIH Study ) of aProduct [ * * * ] ( v ) Initiation of Manufacture of the CTM that is suitable for a Product for a Phase III Clinical Trial by or onbehalf of [COMPANY] following technology transfer ( whereas shall mean the firstsuccessful completion of the Manufacturing of an engineering run by or on behalf of [COMPANY] [ * * * ] ( vi ) Dosing of the first subject in the first Phase III Clinical Trial of such Product in a Major Market Country [ * * * ] 26 Development Event Development Payment(vii ) First Commercial Sale of such Product by [COMPANY], its Affiliates or Sublicensees in the United States [ * * * ] ( viii ) First Commercial Sale of such Product by [COMPANY], its Affiliates or Sublicensees in at least three of theMajor EU Market Countries [ * * * ] ( ix ) First Commercial Sale of such Product by [COMPANY], its Affiliates or Sublicensees in Japan [ * * * ] Each of the Development Payments set forth above will be payable one time only ( regardless of the number of Candidates or Products withrespect to which, or the number of times with respect to any Candidate or Product, the specified Development Event occurs ) . NoDevelopment Payments will be payable by [COMPANY] for any subsequent Candidate or Product regardless of the number of Candidates orProducts Developed . For clarification, if one Candidate or Product replaces another Candidate or Product in Development, then suchreplacement Candidate or Product will only be subject to Development Payments that have not previously been triggered by one or moreprior Candidates or Products . The maximum amount payable by [COMPANY] under this Agreement with respect to all Development Payments if allDevelopment Events occur will be [ * * * ]